The stock of Aeterna Zentaris Inc. (NASDAQ:AEZS) hit a new 52-week low and has $0.74 target or 8.00 % below today’s $0.80 share price. The 9 months bearish chart indicates high risk for the $16.14M company. The 1-year low was reported on Dec, 15 by Barchart.com. If the $0.74 price target is reached, the company will be worth $1.29M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 1.51% or $0.0123 during the last trading session, reaching $0.8002. About 95,451 shares traded. Aeterna Zentaris Inc. (NASDAQ:AEZS) has declined 76.83% since December 15, 2018 and is downtrending. It has underperformed by 76.83% the S&P500.

Analysts await Aeterna Zentaris Inc. (NASDAQ:AEZS) to report earnings on March, 24. They expect $-0.12 earnings per share, up 61.29 % or $0.19 from last year’s $-0.31 per share. After $-0.02 actual earnings per share reported by Aeterna Zentaris Inc. for the previous quarter, Wall Street now forecasts 500.00 % negative EPS growth.

More notable recent Aeterna Zentaris Inc. (NASDAQ:AEZS) news were published by: Finance.Yahoo.com which released: “Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for – Yahoo Finance” on October 29, 2019, also Globenewswire.com with their article: “Aeterna Zentaris Provides Corporate Update Nasdaq:AEZS – GlobeNewswire” published on June 06, 2019, Globenewswire.com published: “Aeterna Zentaris Announces FDA Approval of Macrilenâ„¢ (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency – GlobeNewswire” on December 20, 2017. More interesting news about Aeterna Zentaris Inc. (NASDAQ:AEZS) were released by: Seekingalpha.com and their article: “CRISPR Therapeutics and ReWalk Robotics among healthcare gainers; Aeterna Zentaris and Genocea Biosciences among losers – Seeking Alpha” published on June 07, 2019 as well as Globenewswire.com‘s news article titled: “Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilenâ„¢ in United States and Canada – GlobeNewswire” with publication date: November 01, 2018.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company has market cap of $16.14 million. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It currently has negative earnings. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link